Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline, Ursodiol, and Empagliflozin in T2DM with Fatty Liver
NCT04910178Phase 4Completed
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin, pentoxifylline, ursodeoxycholic acid in non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM). Started Dec 2020; status: completed.
02
Drugs
empagliflozinpentoxifyllineursodeoxycholic acid
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04910178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910178.